There are 399 cancer drugs currently in development, the Pharmaceutical Research and Manufacturers of America (PhRMA) has reported. The association's annual biopharmaceutical research survey also indicated that many of these drugs are possible breakthrough cancer treatments, while others involve potential new indications for existing medicines.
Currently, 178 biopharmaceutical companies and the National Cancer Institute are conducting research into possible cancer cures and treatments. All the medicines in development are either in clinical trials or in FDA review. Of the 399 medicines, 62 are for lung cancer, 49 are for breast cancer, 50 are for prostate cancer, and 35 are for colorectal cancer. Other potential medicines focus on kidney cancer, pancreatic cancer, brain cancer, skin cancer, and ovarian cancer, among others. Furthermore, companies are working on medicines to enhance the quality of life for individuals receiving cancer treatment.
"Anyone fighting cancer or anyone who has beaten it knows the importance of these medicines and this research," said Billy Tauzin, PhRMA president and chief executive officer. "Sometimes, the hope that one of these new medicines will work for you is what keeps you fighting the disease. The real reward for the huge research and development investment in these new medicines comes when one of these treatments helps save lives or allows patients to go home cancer-free."